Levolta Pharmaceuticals is a global biopharmaceutical company that is pioneering and delivering therapies to transform the lives of patients. We are developing novel treatments for a broad range of illnesses, including those patients suffering from diseases associated with rheumatology, immunology and cancer.
Levolta’s lead product, VOLT01, is a novel zoledronic acid combination that has demonstrated an enhanced therapeutic index, leading to a better efficacy and safety profile vs Novartis’ Reclast®. VOLT01 is currently in phase III clinical trials.
Levolta welcomes the opportunity to partner and collaborate on future developments with the investment community.
Please direct all inquiries to:
Richard Becker, CEO
firstname.lastname@example.org or (848) 702-0682.